New directions in the treatment of imatinib failure and/or resistance

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) treatment often involves tyrosine kinase inhibitors (TKIs).
• A subset of CML patients exhibit primary or secondary resistance/intolerance to imatinib, necessitating alternative therapies.
• Limited options previously included chemotherapy, interferon alfa, or stem cell transplantation.

Purpose of the Study:

• To review the efficacy and role of second-generation TKIs (nilotinib, dasatinib) in CML treatment following imatinib failure.
• To discuss the current treatment landscape and emerging therapeutic strategies for resistant or intolerant CML patients.

Main Methods:

• Review of phase II clinical trial data for nilotinib and dasatinib.
• Analysis of current treatment guidelines and recommendations for second-line CML therapy.
• Exploration of sequential TKI therapy and novel treatment modalities.

Main Results:

• Nilotinib and dasatinib demonstrate strong clinical efficacy in CML patients resistant or intolerant to imatinib.
• These agents are now recommended as second-line therapies, though agent selection is often based on tolerability due to lack of head-to-head comparative data.
• Both nilotinib and dasatinib show activity in sequential treatment after prior TKI failure.

Conclusions:

• Second-generation TKIs have significantly improved treatment outcomes for imatinib-resistant/intolerant CML.
• Sequential TKI therapy is a viable strategy for managing CML progression.
• Ongoing research into novel TKIs and other agents aims to provide further options for patients with advanced or refractory CML.